CD19 CAR T细胞治疗复发性/耐药性扩散性大B细胞淋巴瘤的非老年患者
Jotaro Yamamoto1, Daisuke Kaji1,2,3, Mika Kuno1
1Department of Hematology, Toranomon Hospital, Tokyo, Japan.
概括
化学抗原受体 (CAR) T细胞疗法在患有大B细胞淋巴瘤的老年人中表现有前途. 一名90岁的患者耐受好CAR T细胞治疗,副作用可控,在非老年人群中证明可行性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 老年医学 老年医学
背景情况:
- 化学抗原受体 (CAR) T细胞疗法改变了复发性/耐药性大B细胞淋巴瘤的治疗方法.
- 关于超老年人群中CAR-T细胞治疗的疗效和安全性的数据有限.
研究的目的:
- 报告第一个非老年亚洲患者成功接受CAR T细胞疗法治疗复发/耐药扩散大B细胞淋巴瘤的病例.
- 评估 lisocabtagene maraleucel 在超老年患者中的可行性,耐受性和安全性.
主要方法:
- 一名患有复发性/耐药性扩散性大B细胞淋巴瘤的90岁女性接受了 lisocabtagene maraleucel.
- 老年人的评估,包括认知功能和日常生活活动,明智的治疗候选人.
- 治疗细胞因子释放综合征 (CRS) 用托西利祖马布和德克萨米他松.
主要成果:
- 患者经历了可控的1级和2级CRS,通过早期干预成功治疗.
- 没有观察到免疫效应细胞相关的神经毒性综合征或传染性并发症.
- 过渡性 2-4 级细胞衰减通过支持性护理得到管理,患者在 28 日出院.
结论:
- 在选择的大型B细胞淋巴瘤的非老年患者中,CAR T细胞疗法是可行的和可以容忍的,并得到了全面的老年医学评估的支持.
- 迅速管理CRS对于在老年人中安全提供CAR T细胞治疗至关重要.
- 这一案例扩大了高级年龄组中CAR T细胞治疗的证据基础.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K